High-speed Rail Coating Market Forecasts to 2032 – Global Analysis By Coating Type (Protective Coatings, Aesthetic Coatings and Functional Coatings), Material (Acrylic, Epoxy, Polyurethane, Plastisol, Polyester, Fluoro Polymers and Other Materials), Techn

According to Stratistics MRC, the Global CT/NG Testing Market is accounted for $2.16 billion in 2025 and is expected to reach $4.38 billion by 2032 growing at a CAGR of 10.6% during the forecast period. CT/NG testing refers to diagnostic tests used to detect Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), two of the most common sexually transmitted infections (STIs) worldwide. These tests are essential for early diagnosis and treatment because, although both infections frequently show no symptoms, if treatment is not received, they can cause major health problems like pelvic inflammatory disease and infertility. Typically, CT/NG testing uses nucleic acid amplification tests (NAATs), which can be carried out with urine samples, vaginal swabs, or other specimen types and have high sensitivity and specificity. Regular screening is a crucial public health tactic to stop the spread of these infections, particularly among sexually active people.

According to the Centers for Disease Control and Prevention (CDC), over 2.4 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2023. Chlamydia accounted for more than 1.6 million cases, making it the most commonly reported sexually transmitted infection (STI).

Market Dynamics:

Driver:

Growing STI prevalence

One of the major factors propelling the CT/NG testing market is the rising global incidence of chlamydia and gonorrhea. Over 700,000 cases of gonorrhea and over 1.6 million cases of chlamydia were reported in the United States in 2021 alone, according to the CDC. Because asymptomatic infections often go undiagnosed, these figures are probably underestimates. According to the World Health Organization (WHO), Chlamydia and gonorrhea account for a significant portion of the 374 million new curable STI infections that occur worldwide each year. In order to stop the disease from spreading further and to start treatment as soon as possible, diagnostic testing has increased dramatically as a result of this high disease burden.

Restraint:

Expensive advanced diagnostic testing

The high cost of advanced diagnostic technologies, like nucleic acid amplification tests (NAATs), can restrict access, particularly in low- and middle-income nations, despite their high sensitivity and specificity. Underfunded public health systems or smaller clinics may not be able to afford the costly reagents, specialized equipment, and skilled personnel needed for these tests. Widespread adoption is hampered by this financial obstacle, especially in places where STI testing funding is scarce. Moreover, the out-of-pocket expenses can also discourage people from getting tested on a regular basis, especially for populations without insurance or in areas without public healthcare systems.

Opportunity:

Integration of telemedicine and digital health

The increasing use of telemedicine platforms and digital health solutions is opening up new avenues for CT/NG testing. People can easily and discreetly access STI services with at-home testing kits and app-based consultations. These platforms can support electronic prescriptions for treatment, remote result delivery, and instructions for sample collection. Better data collection and contact tracing are also made possible by digital health tools, which support public health surveillance. Additionally, diagnostic companies have a long-term opportunity to bundle testing with digital support services, as the COVID-19 pandemic has accelerated this trend and demonstrated that both patients and providers are growing more at ease with virtual care.

Threat:

Competition in low-resource environments from syndromic management

Due to a lack of funding and access to laboratory testing, syndromic management of STIs is still widely used in many developing nations. This method reduces the need for diagnostics by treating symptoms without the need for confirmatory testing, despite being less accurate. The continued use of syndromic management jeopardizes CT/NG testing's ability to expand, particularly in public health systems where cost is a key consideration. Furthermore, diagnostic adoption may remain restricted in high-burden nations where it is most needed unless point-of-care tests become more accessible and incorporated into current procedures.

Covid-19 Impact:

The COVID-19 pandemic had a mixed effect on the CT/NG testing market. At first, it caused testing services to be disrupted because of supply chain disruptions, the overburden on the healthcare system, and the reallocation of laboratory resources to SARS-CoV-2 diagnostics. As a result of the suspension or reduction of routine screening programs for STIs, such as gonorrhea and chlamydia, in many areas, testing volumes temporarily decreased and diagnoses were delayed. The pandemic did, however, also hasten the uptake of point-of-care diagnostics, telemedicine, and self-collection kits, establishing the foundation for more accessible and decentralized STI testing.

The assays & kits segment is expected to be the largest during the forecast period

The assays & kits segment is expected to account for the largest market share during the forecast period. The extensive use of molecular diagnostic tests, like nucleic acid amplification tests (NAATs), which are very sensitive and specific for identifying CT/NG infections, is what is causing this dominance. Because of their simplicity of use, quick turnaround times, and compatibility with automated platforms, these assays are frequently utilized in clinical laboratories, hospitals, and even at-home testing kits. Moreover, assay-based solutions have become increasingly popular due to the increasing need for early and precise diagnosis, particularly in asymptomatic individuals. As a result, this market segment now accounts for the largest portion of market revenue.

The home care settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home care settings segment is predicted to witness the highest growth rate. The primary drivers of this growth are the growing demands for STI screening that are accessible, convenient, and private. Telehealth-based diagnostic services and at-home sample collection kits have become increasingly popular, especially since the COVID-19 pandemic changed patient preferences. By enabling people to send samples to accredited labs and perform self-tests without having to visit medical facilities, these solutions improve testing frequency and lessen stigma. Additionally, self-testing's ease of use, growing awareness, and technological developments are anticipated to greatly speed up this market's growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, mainly due to the region's population size, rising STI rates, and growing sexual health consciousness. Furthermore, the region's market dominance is largely due to growing access to advanced diagnostic technologies in nations like China, India, Japan, and Australia, as well as expanding healthcare infrastructure and government initiatives supporting STI screening programs. The market in Asia-Pacific is expanding due to the growing use of point-of-care testing kits and nucleic acid amplification tests (NAATs), which has made the region the world's most prominent location for CT/NG testing.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, motivated by a robust healthcare system, a high level of knowledge about STDs, and the broad use of cutting-edge diagnostic tools. Strong reimbursement practices, expanding screening initiatives and continuous R&D efforts all contribute to the market's expansion. Additionally, variables supporting the strong growth of the CT/NG testing market in North America include the availability of highly sensitive and quick testing techniques, as well as rising public and private investments in sexual health programs.

Key players in the market

Some of the key players in CT/NG Testing Market include Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Binx Health, Inc., Abbott Laboratories, Hologic Inc., Siemens Healthineers AG, ELITech Group SAS, Danaher Corporation, Seegene, Inc., Genetic Signatures Ltd., Becton, Dickinson and Company (BD), Qiagen N.V., Meridian Bioscience Inc. and PerkinElmer Inc.

Key Developments:

In February 2025, Bio-Rad Laboratories, Inc launched its TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits. The new kits are designed to offer a convenient method to label any antibody with one of Bio-Rad’s StarBright Dyes, for use in either flow cytometry or fluorescent western blot experiments. The new two-kit system provides researchers access to Bio-Rad’s StarBright Blue and StarBright Violet Dyes, employing Bio-Rad’s SpyTag and SpyCatcher technology to conjugate a dye to an antibody of choice.

In February 2025, Thermo Fisher Scientific Inc. announced that the company has entered into a definitive agreement with Solventum to acquire Solventum’s Purification & Filtration business for approximately $4.1 billion in cash. Solventum’s Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications.

In November 2024, Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida’s R&D portfolio includes pre-clinical and clinical-stage off-the-shelf CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms.

Products Covered:
• Assays & Kits
• Instruments/Analyzers

Testing Types Covered:
• Laboratory Testing
• Point-of-care (POC) Testing

End Users Covered:
• Diagnostic Laboratories
• Hospitals & Clinics
• Home Care Settings
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements